Q4-2012 was the second consecutive quarter in which there was a slowdown in growth for retinal procedures.
An FDA advisory panel has been scheduled for April 8 to consider Bausch + Lomb’s premarket approval application for the Trulign Toric accommodating IOL.
The Glaukos iStent played a large role in this increase, as the device entered its second full quarter since its US launch.
Dry eye treatments and technologies are expected to generate global revenues of $2.4 billion in 2013, with that tally climbing to nearly $3.0 billion in 2018.
Steady revenue growth of 5 percent is forecast for established retinal surgical devices over the next five years, but we look for new technologies to fuel growth of 6.6 percent overall.
You are not currently logged in.
©2017 Market Scope
Lost your Password